Get the Stockscreener App
282.87
1.00%
2.80
After Hours:
282.00
-0.87
-0.31%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $282.87, with a volume of 2.07M.
It is up +1.00% in the last 24 hours and down -10.48% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$280.07
Open:
$279.455
24h Volume:
2.07M
Relative Volume:
0.87
Market Cap:
$151.74B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
20.10
EPS:
14.07
Net Cash Flow:
$6.28B
1W Performance:
-3.96%
1M Performance:
-10.48%
6M Performance:
-4.56%
1Y Performance:
+6.10%
1-Day Range:
$277.64
$283.64
1-Week Range:
$257.80
$297.32
52-Week Range:
$257.80
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
282.87 | 151.74B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
795.35 | 755.90B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
106.80 | 474.49B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
155.01 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.93 | 323.26B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
101.64 | 257.11B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
FY2024 Earnings Forecast for Amgen Issued By Leerink Partnrs - MarketBeat
Erste Asset Management GmbH Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Paradigm Capital Management LLC NV Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bellevue Group AG - MarketBeat
Caisse DE Depot ET Placement DU Quebec Purchases 115,210 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
TRUE Private Wealth Advisors Sells 1,938 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Biotech Experience celebrates reaching 1 million students worldwide - The Business Journals
Amgen Inc. (AMGN): A Bull Case Theory - Yahoo Finance
Icon Wealth Advisors LLC Sells 1,882 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? - Yahoo Finance
Public Sector Pension Investment Board Buys 2,900 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE - PR Newswire
Wide Trading Range For Amgen Stock Makes This Option Shine - Yahoo! Voices
Amgen, Boeing share losses lead Dow's 200-point fall - MSN
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Captrust Financial Advisors Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
AMGN: 3 Biotech Stocks with Promising Pipelines to Watch - StockNews.com
Rockefeller Capital Management L.P. Grows Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Martingale Asset Management L P Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Northwest & Ethical Investments L.P. - MarketBeat
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? - sharewise
Is Novo Nordisk Stock a Buy? - The Motley Fool
Amgen Inc. (NASDAQ:AMGN) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Leerink Partnrs Has Pessimistic View of Amgen Q4 Earnings - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
CreativeOne Wealth LLC Boosts Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (AMGN) Gross Profit : $19,676 Mil (TTM As of Sep. 2024) - GuruFocus.com
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity? - Yahoo Finance
Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Amgen Drug Delivers More Weight Loss Than Competitors - Newsweek
New Apprentice Program Draws Talent from Unexpected Sources - Amgen
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You (NASDAQ:AMGN) - Seeking Alpha
Amgen stock holds Buy rating, TD Cowen highlights MariTide's competitive edge in obesity treatment - Investing.com
BNP Paribas Has $5.40 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’ - MSN
Healthcare of Ontario Pension Plan Trust Fund Buys 303,016 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide achieves up to 20% weight loss in Phase 2 trial - World Pharmaceutical Frontiers
Glenmede Trust Co. NA Sells 42,532 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study - Yahoo Finance
Fmr LLC Buys 181,703 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The Manufacturers Life Insurance Company Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen's Weight Loss Result Is a Win for Eli Lilly - sharewise
Fisher Asset Management LLC Acquires 17,974 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen share price plummets despite Phase II weight loss success - Clinical Trials Arena
Amgen: Checks All The Wrong Boxes (NASDAQ:AMGN) - Seeking Alpha
AMGN Stock: MariTide Faces Dropout Challenges - Value the Markets
Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For - Citeline News & Insights
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - MedCity News
Stocks Open Mixed. Amgen Is Dragging on the Dow. - Barron's
Amgen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):